Oral thin films contain an active pharmaceutical ingredient (API) embedded within a polymeric matrix. Evaluating particle size directly in the film can help formulation teams understand particle distribution while preserving the particles’ in-film state. This case study outlines how optical microscopy combined with the CLAIRITY™ PARTICLE Module can support particle characterization during formulation development and provide visual evidence relevant to regulatory justification.
In oral thin films, the API is dispersed within a polymeric matrix. The analytical workflow therefore needs to visualize embedded particles without unnecessarily disturbing their native state, while helping analysts assess particle size, agglomeration, and dispersion uniformity. A workflow based on microscopy and image analysis offers direct visual context alongside quantitative measurements
With careful sample preparation and upright optical microscopy, embedded API particles can be visualized directly within the film. Images can then be evaluated using the CLAIRITY™ PARTICLE Module to turn microscopic observations into structured particle-analysis data.
This workflow connects microscopic observations with quantitative, reproducible particle-analysis data. It can support formulation-development decisions by helping teams evaluate particle size and distribution, identify potential agglomeration, and review dispersion uniformity. The combination of image evidence and quantitative outputs can also contribute to documentation prepared for regulatory justification.
Optical microscopy paired with the CLAIRITY™ PARTICLE Module provides a practical approach for assessing API particles directly within oral thin films. By combining automated detection and classification with particle-size distribution metrics and visual review, the workflow supports a more structured understanding of particle characteristics during product development.